Akero is a clinical-stage company founded to develop transformational treatments for patients with serious metabolic diseases marked by high unmet medical need.

We began with an engineered protein called efruxifermin (EFX), which we licensed from Amgen and are developing for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). MASH is a serious liver disease caused by metabolic dysregulation for which there are limited treatment options. We believe restoring whole-body metabolic balance is the key to addressing metabolic dysregulation and bringing impactful therapeutic options to patients—and we believe EFX is ideally suited for this challenge.

In 2025, Novo Nordisk acquired Akero to unlock the full potential of efruxifermin and reach more patients living with MASH.